- همه نشریات
- نشریات علمی سازمان تحقیقات، آموزش و ترویچ کشاورزی
- مجلات ترویجی سازمان تحقیقات، آموزش و ترویج کشاورزی
- سایر نشریات سازمان تحقیقات، آموزش و ترویج کشاورزی
- نشریات علمی انجمن ها
- علوم آب و خاک
- علوم اقتصاد و ترویج کشاورزی
- علوم جنگل, مرتع و آبخیزداری
- علوم دامی و شیلات
- علوم زراعی و باغی
- علوم گیاهپزشکی
- علوم مهندسی و مکانیزاسیون کشاورزی
- نشریات با زبان انگلیسی
- نشریات با زبان فارسی
- نشریات دانشگاه آزاد اسلامی
- نشریات علمی
پیوندهای مفید
اخبار و اعلانات
آمار
| تعداد نشریات | 281 |
| تعداد نشریات سازمان | 80 |
| تعداد شماره‌ها | 2,458 |
| تعداد مقالات | 28,410 |
| تعداد مشاهده مقاله | 16,616,203 |
| تعداد دریافت فایل اصل مقاله | 12,860,622 |
Comparative evaluation of biosimilar Trastuzumab with reference Trastuzumab activity in HER2-positive breast cancer patients | ||
| Archives of Razi Institute | ||
| مقالات آماده انتشار، پذیرفته شده، انتشار آنلاین از تاریخ 02 آذر 1401 | ||
| نوع مقاله: Original Articles | ||
| شناسه دیجیتال (DOI): 10.22092/ari.2022.360239.2566 | ||
| نویسندگان | ||
Vana AbdulHameed Saeed  1؛ Nidhal AK. Mohammed2
| ||
| 1Hawler Medical University, College of Medicine. Department of Basic Science, Erbil, Iraq. Tel: 009647507692757 / | ||
| 2Pharmacology Unit, Dept. Basic sciences, College of Medicine, Hawler Medical University/ email: nidhal.abdulkader@hmu.edu.krd | ||
| چکیده | ||
| Background One of the breast cancer subtypes, epidermal growth factor receptor 2 (HER2), accounts for 15% of all breast cancers and is characterized by aggressive behavior and a poor prognosis. For patients with HER2-positive breast cancer, trastuzumab, a monoclonal antibody that targets HER2 receptors, is prescribed in addition to chemotherapy to increase their chances of survival. However, the high expense of this therapy makes it impossible for patients in developing nations to easily afford to undergo this biological therapy. Trastuzumab biosimilars were consequently launched as a substitute that offers comparable effectiveness but at a reduced price. By monitoring serum levels of the tumor biomarker CA15-3 and evaluating NT pro-BNP for the adverse cardiac effects of both therapy in HER2 positive breast cancer patients before and after 6 cycles of biological therapy, this study compares the biological activity and cardiac safety of reference trastuzumab with biosimilar trastuzumab. Patients and Methods 36 females with metastatic and early stage HER2-positive breast cancer who visited the oncology department at Rizgary Hospital were included in this prospective research. The patients' ages ranged from 30 to 80. 18 individuals got reference trastuzumab, while the remaining 18 also received chemotherapy and biosimilar trastuzumab. Each patient had a data sheet created for them that contained details from hospital-reserved files.` Results In the Herceptin group, there is an insignificant difference in the median of CA15-3, No significant difference was detected between the means of NT proBNP before and after treatment. In the Biosimilar group, there was a significant reduction in the median CA15-3. Also for BNP, there is a significant increase in the level of NT proBNP before and after treatment Conclusion Evaluating the association of trastuzumab-induced cardiotoxicity during breast cancer treatment with different factors, we discovered that there may be an increased risk of cardiotoxicity after trastuzumab treatment | ||
| کلیدواژه‌ها | ||
| breast cancer؛ chemotherapy؛ HER2-positive breast cancer؛ reference trastuzumab؛ biosimilar trastuzumab | ||
|
آمار تعداد مشاهده مقاله: 28 |
||
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب